[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630642":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":60,"collaborators":62,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":26,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":93,"whyStopped":26,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Moogene Medi Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"AD-303A Topical","EXPERIMENTAL","Participants receive topical AD-303A applied to the scalp according to the study protocol.",[13],"Drug: AD-303A",{"label":15,"type":16,"description":17,"interventionNames":18},"Oral AD-3031","ACTIVE_COMPARATOR","Participants receive oral AD-3031 administered according to the study protocol.",[19],"Drug: AD-3031",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","AD-303A","Topical AD-303A applied to the scalp according to the study protocol.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"AD-3031","Oral AD-3031 administered according to the study protocol.",[15],[32],{"name":33,"affiliation":34,"role":35},"Seung Hwan Lee, Ph.D.","Seoul National University Hospital","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Ji-Hye Lee, Ph.D.","CONTACT","82-31-8027-6150","jhlee@moogene.com",{"name":43,"role":39,"phone":40,"phoneExt":26,"email":44},"Tae-Jong Yoon, Ph.D.","moogenemedi@moogene.com",[46],{"facility":34,"status":26,"city":47,"state":47,"zip":48,"country":49,"countryCode":26,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Seoul","03080","South Korea",{"type":51,"coordinates":52},"Point",[53,54],126.9784,37.566,{"lat":54,"lon":53},[57],{"name":33,"role":39,"phone":58,"phoneExt":26,"email":59},"82-2-2072-2343","leejh413@snu.ac.kr",{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[63],{"name":34,"class":64},"OTHER","100630642","phase-1-assessment-of-dutasteride-topical-solution-in-male-androgenetic-alopecia-100630642",false,"NCT07490327","Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia","A Randomized, Open-label, Single and Multiple-dose, Parallel-design Phase 1\u002F2a Clinical Trial to Evaluate the Pharmacokinetics\u002FPharmacodynamics and Safety of AD-303A and Oral Administration of AD-3031 in Male Androgenetic Alopecia Patients","Inclusion Criteria:\n\n* Male participants aged 19 to 55 years.\n* Clinical diagnosis of androgenetic alopecia.\n* Healthy as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests.\n* Willing and able to comply with all study procedures and visit schedules.\n\nExclusion Criteria:\n\n* History or presence of dermatologic conditions affecting the scalp other than androgenetic alopecia.\n* Prior hair transplantation or scalp surgery that may affect evaluation of hair growth.\n* Use of medications known to affect hair growth (e.g., finasteride, dutasteride, minoxidil) within 6 months prior to screening.",true,"MALE","19 Years","55 Years",{"count":77,"type":78},30,"ESTIMATED","INTERVENTIONAL",[81,82],"PHASE1","PHASE2","This is a randomized, open-label phase 1\u002F2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.",[85],"Androgenetic Alopecia",[87,85,88,89,90,91,92],"AD-303A \u002F AD-3031","Dutasteride","Topical","5-Alpha Reductase Inhibitor","Pharmacokinetics","Safety","NOT_YET_RECRUITING","2026-03-19",{"date":96,"type":97},"2026-03-24","ACTUAL",{"date":99,"type":78},"2026-04",{"date":101,"type":78},"2026-12",{"name":5,"class":6},1]